Skip to main content
Top

Breast Cancer Research and Treatment

Issue 1/2008

Content (19 Articles)

Preclinical Study

TGFβ2 and TβRII are valid molecular biomarkers for the antiproliferative effects of tamoxifen and tamoxifen metabolites in breast cancer cells

Miriam B. Buck, Janet K. Coller, Thomas E. Mürdter, Michel Eichelbaum, Cornelius Knabbe

Preclinical Study

Effects of polyamine depletion by α-difluoromethylornithine on in vitro and in vivo biological properties of 4T1 murine mammary cancer cells

John Yoonkeun Jun, James W. Griffith, Richard Bruggeman, Sharlene Washington, Laurence M. Demers, Michael F. Verderame, Andrea Manni

Open Access Preclinical Study

Loss of expression of FANCD2 protein in sporadic and hereditary breast cancer

Petra van der Groep, Michael Hoelzel, Horst Buerger, Hans Joenje, Johan P. de Winter, Paul J. van Diest

Preclinical Study

Farnesol, a mevalonate pathway intermediate, stimulates MCF-7 breast cancer cell growth through farnesoid-X-receptor-mediated estrogen receptor activation

Fabrice Journe, Guy Laurent, Carole Chaboteaux, Denis Nonclercq, Virginie Durbecq, Denis Larsimont, Jean-Jacques Body

Clinical Trial

Prophylactic mastectomy in familial breast carcinoma. What do the pathologic findings learn us?

Karin Leunen, Maria Drijkoningen, Patrick Neven, Maria-Rose Christiaens, Chantal Van Ongeval, Eric Legius, Frédéric Amant, Patrick Berteloot, Ignace Vergote

Clinical Trial

Multicenter phase II trial of neoadjuvant exemestane for postmenopausal patients with hormone receptor-positive, operable breast cancer: Saitama Breast Cancer Clinical Study Group (SBCCSG-03)

Hiroyuki Takei, Kimito Suemasu, Kenichi Inoue, Tsuyoshi Saito, Katsuhiko Okubo, Junichi Koh, Kazuhiko Sato, Hitoshi Tsuda, Masafumi Kurosumi, Toshio Tabei

Epidemiology

Tumor susceptibility and prognosis of breast cancer associated with the G870A polymorphism of CCND1

Cheng-Ping Yu, Jyh-Cherng Yu, Chien-An Sun, Ching Tzao, Jar-Yi Ho, Amy Ming-Fang Yen

Epidemiology

Intake of fruits, and vegetables in relation to breast cancer risk by hormone receptor status

Jolanta Lissowska, Mia M. Gaudet, Louise A. Brinton, Beata Peplonska, Mark Sherman, Neonila Szeszenia-Dabrowska, Witold Zatonski, Montserrat Garcia-Closas

Epidemiology

BARD1 and breast cancer in Poland

Anna Jakubowska, Cezary Cybulski, Anna Szymańska, Tomasz Huzarski, Tomasz Byrski, Jacek Gronwald, Tadeusz Dębniak, Bohdan Górski, Elżbieta Kowalska, Steven A. Narod, Jan Lubiński

Epidemiology

Dietary animal-derived iron and fat intake and breast cancer risk in the Shanghai Breast Cancer Study

Asha R. Kallianpur, Sang-Ah Lee, Yu-Tang Gao, Wei Lu, Ying Zheng, Zhi-Xian Ruan, Qi Dai, Kai Gu, Xiao-Ou Shu, Wei Zheng

Preclinical Study/Clinical Trial/Epidemiology/Invited Commentary

Circulating endothelial progenitor cells correlate to stage in patients with invasive breast cancer

Rakhi P. Naik, David Jin, Ellen Chuang, Ellen G. Gold, Eleni A. Tousimis, Anne L. Moore, Paul J. Christos, Tatiana de Dalmas, Diana Donovan, Shahin Rafii, Linda T. Vahdat

Preclinical Study/Clinical Trial/Epidmiology/Invited Commentary

Screening for ATM sequence alterations in African-American women diagnosed with breast cancer

Ariel E. Hirsch, David P. Atencio, Barry S. Rosenstein

Preclinical Study/Clinical Trial/Epidemiology/Invited Commentary

Quantitative detection of circulating epithelial cells by Q-RT-PCR

Vladimir V. Iakovlev, Rashmi S. Goswami, Jonathan Vecchiarelli, Nona C. R. Arneson, Susan J. Done

Letter to the Editor

No association between BRCA mutations and sex ratio in offspring of Pakistani BRCA mutation carriers

Muhammad U. Rashid, Diana Torres, Anbreen Zaidi, Farah Rasheed, Faisal Sultan, Abdul R. Shakoori, Asim Amin, Ute Hamann

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine